Eric Frommé, M.S.
About Eric Frommé, M.S.
Eric Frommé, M.S., is a Technical Product Team Leader at Bristol Myers Squibb, with over 15 years of experience in API development and manufacturing in the pharmaceutical industry.
Company
Eric Frommé currently works at Bristol Myers Squibb in New Jersey, United States. Bristol Myers Squibb is a global biopharmaceutical company that is engaged in discovering, developing, and delivering innovative medicines. The company focuses on therapeutic areas that include oncology, cardiovascular, and immunology.
Title
At Bristol Myers Squibb, Eric Frommé serves as the Technical Product Team Leader (TPT L). He also holds the position of Technical Leader, Drug Substance (API) Manufacturing Science and Technology. His roles involve leading technical product teams and managing the drug substance manufacturing science and technology efforts.
Education and Expertise
Eric Frommé holds a Master of Science (M.S.) degree in Chemical and Biochemical Engineering with a concentration in Pharmaceutical Engineering from Rutgers, The State University of New Jersey-New Brunswick. He also achieved a Bachelor of Science (B.S.) degree in Chemical Engineering with a focus on Entrepreneurial Business Management from Case Western Reserve University. His expertise includes statistical Design of Experiment (DoE) using JMP and MiniTab, Quality by Design analysis in process development and validation, equipment and process validation, and API development and manufacturing.
Professional Background
Eric Frommé's professional background includes various roles in the pharmaceutical industry. He worked at Celgene from 2011 to 2020 in positions such as Technical Leader, Drug Substance (API) Manufacturing Science and Technology, Associate Director, Pharmaceutical Sciences and Technology, Drug Substance Development, Senior Manager, Manager, and Associate Manager. Additionally, he worked at sanofi-aventis from 2005 to 2011 in roles including Supervisor I, Scientist I, and Associate Scientist. He has experience working at other companies like Forest Laboratories and sanofi-sythélabo as well.
Achievements
Eric Frommé has played a significant role in the pharmaceutical industry, notably supporting the commercialization and technical transfer of products with over $12 billion in sales, including Revlimid, Otezla, Idhifa, Vidaza, and Thalomid. He was instrumental in the approval of a new solid oral dose GMP facility by the EMA inspectorate and authored all manufacturing batch records for clinical trial materials. His extensive experience includes coordinating the transfer of new formulations to clinical manufacturing and leading the development and manufacturing of highly-potent oncology products.